Price Alert

BioCryst Pharmaceuticals ... (BCRX)

NASDAQ: BCRX · Real-Time Price · USD

8.37

-0.08 (-0.95%)

At close: Aug 15, 2025, 10:19 AM

-0.95% (1D)

Bid	8.36
Market Cap	1.76B
Revenue (ttm)	557.51M
Net Income (ttm)	-35.71M
EPS (ttm)	-0.18
PE Ratio (ttm)	-46.49
Forward PE	15.38
Analyst	Buy

Ask	8.37
Volume	540,150
Avg. Volume (20D)	3,913,816.5
Open	8.37
Previous Close	8.45
Day's Range	8.37 - 8.52
52-Week Range	6.02 - 11.31
Beta	1.10

About BCRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BCRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BCRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

BioCryst Pharmaceuticals Inc. is scheduled to release its earnings on Nov 3, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+9.81%

BioCryst Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription

3 months ago

+23.52%

BioCryst Pharmaceuticals shares are trading higher after the company reported a Q1 sales beat.

News

1 week ago · seekingalpha.com

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Babar Ghias - CFO & Head of Corporate Development Charles K. Gayer - Presi...

1 week ago · zacks.com

BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.06 per share a year ago.

1 week ago · fool.com

BioCryst (BCRX) Q2 Revenue Jumps 50%

2 weeks ago · zacks.com

BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock

BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.

2 weeks ago · zacks.com

BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · zacks.com

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

1 month ago · zacks.com

BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).